Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Approved
Approved. Desmopressin is an FDA-approved drug product for specific indications. Approval is specific to the product, indication, and route.
Drugs@FDA: desmopressin (NDA 017922)By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 5/5. 3,800 PubMed citations indexed.
Synthetic vasopressin analog with high V2 receptor selectivity; reduces renal water excretion and may enhance memory consolidation via V1 receptor activation in hippocampus.
What the literature studies
ADH Replacement & Memory Enhancement
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
hyponatremia risk, especially in elderly.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.